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Abstract 
Purpose: To compare the efficacy of temozolomide, radiation and stem cell therapy in glioma 
management. 
Methods: A total of 112 patients with glioblastoma were divided into four groups, each of 28 patients. 
Group I received daily temozolomide at 150 mg/m2; Group II radiotherapy of 30.0 Gy; Group III 
mesenchymal stem cells only; and Group IV all three treatments (temozolomide 100 mg/m2 + 30.0 Gy of 
radiotherapy + two infusions of mesenchymal stem cells, weekly for 3 weeks. All patients were 
assessed 1, 6, and 12 months following the conclusion of treatment. 
Results: Of Group I patients, the maximum improvement in tumor diameter was 58 % but only 28 % 
ultimately survived. Of Group II patients, the maximum improvement was 49 % but, again, only 28 % 
survived (p = 0.06 for both groups). Of Group III patients, the maximum improvement was 71 % and 40 
% survived. Of Group IV patients, who received all three treatments, the maximum improvement was 80 
%. The survival rate was 60 %.  
Conclusion: Stem cells improved patient outcomes and may be a useful alternative therapy for glioma. 
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Glioblastoma is one of the commonest brain 
tumors, constituting 50–55 % of all such tumors 
[1]. Prognosis is poor for several reasons, of 
which one is recurrence [2]. Other factors include 
the development of resistance to chemotherapy 
and radiotherapy, and advanced patient age. 
Radiotherapy has been the principal 
postoperative therapy for many decades, but is 
not fully effective [3].  The levels of molecular 
markers of glioma progression are higher in 
elderly patients than in younger adults [4-6]. 
Temozolomide has been prescribed to both 
glioma outpatients and inpatients to improve 
survival and the quality of life, as has 
radiotherapy. Both treatment modalities increase 
survival [7,8]. Temozolomide (an alkylating 
agent) has good oral bioavailability and is well 
tolerated, so it is widely used to treat 
glioblastoma [9,10]. 
 
Radiotherapy is one of the best supportive care 
options after surgery [11]. Radiotherapy is well 
tolerated by many patients; however, toxicities do 
develop. Some patients improve after treatment 
[12]. The translational therapies applied over the 
past 50 years do not cure glioma, but do improve 
the survival rate. In recent years, a number of 
innovative therapies have been developed. 
 
Bone marrow-derived stem cells find many 
clinical applications; the cells are easy to harvest 
[13]. Clinically, human mesenchymal stem cells 
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are most often used because they are easily 
isolated and cultured and can be genetically 
modified. 
 
In the present study, we compare temozolomide, 
radiotherapy, and stem cell therapy in terms of 
effectiveness. Self-renewing agents such as 





We recruited a total of 112 patients with 
glioblastoma treated in the Department of 
Neurosurgery, Shanghai Tongji Hospital, 
Shanghai, China, from January 2014 to April 
2016. The study complied with National Institutes 
of Health guidelines [14] and was approved by 
the Institutional Ethics Board of the hospital 
(approval no. STHR 748-19/14). The inclusion 
criteria were newly diagnosed, pathologically 
confirmed glioma and age > 50 years. We 
enrolled both males and females. We excluded 
patients who were already receiving anticancer 
treatment and those younger than 50 years of 
age. Demographic details were collected from 
hospital records. Clinically, all patients had grade 
IV astrocytomas, as defined by the World Health 
Organization (WHO). All patients underwent 
baseline assessment including a total blood 
count and physical examination. Weight, height, 
neurological status, and lifestyle factors were 
obtained from hospital records or with the aid of 
a questionnaire. 
 
Patients were divided into four groups, each 
including 28 of them. Group I consisted of 16 
male and 12 female patients aged 55–68 years. 
They received only temozolomide (150 mg/m2 for 
4 of 25 days; eight cycles). Group II consisted of 
14 male and 14 female patients aged 54–66 
years. They received only radiotherapy (30.0 Gy 
for 2 days each week for 4 weeks). Group III 
consisted of 18 male and 10 female patients 
aged 59–64 years. They received only bone 
marrow mesenchymal stem cells, directly 
injected into the tumor (two injections weekly for 
4 weeks; eight doses in all). Group IV consisted 
of 12 male and 16 female patients aged 50–70 
years. They received all three treatments 
(temozolomide 100 mg/m2 for 4 of every 25 days 
[8 cycles]; 30.0 Gy of radiotherapy in fractions of 
3.7 Gy for 2 days each week for 4 weeks [8 
fractions]; and two doses of mesenchymal stem 
cells weekly for 3 weeks). All patients were 
assessed 1, 6, and 12 months after the 
commencement of treatment. Blood counts were 
checked every month, especially in patients 
receiving temozolomide. All side effects were 
graded using the WHO system [15] and were 
treated when possible. Otherwise, the glioma 





Survival difference between groups was 
considered significant at p < 0.01. Overall 
survivals were compared using the Kaplan-Meier 
method. Improvements in the various groups 
were compared. All statistical analyses were 





Of the 112 glioma patients, 60 (53.6 %) were 
male and 52 (46.4 %) female, and the mean age 
was 56 ± 5.8 years. Study data were analyzed 




Figure 1: A computed tomography (CT) scan of a 
patient taken prior to commencement of therapy 
 
Group I patients had a mean weight of 54 ± 5.4 
kg and a mean height of 162 ± 3.7 cm (Table 1). 
Of the 28 patients, 4 (14.3 %) discontinued 
treatment because of poor prognosis. Fourteen 
(50 %) patients underwent a second course of 
treatment. Six (21.4 %) patients improved by a 
maximum of 58 % (Table 2). The survival rate 
was only 28%. Three (10.7 %) patients died from 
disease progression. Three (10.7 %) developed 
nausea and vomiting; treatment was stopped for 
1 week to deal with these problems, and then 
resumed. Two (7.1 %) patients developed 
neutropenia and one (3.6 %) an intracranial 
hemorrhage (Table 3). 
 
In Group II (radiotherapy), the mean patient age 
was 59 ± 5.9 years, the mean weight was 56 ± 
2.8 kg, and the mean height was 154 ± 3.4 cm. 
The maximum improvement was 49 % (Table 2). 
Survival was poorer than that of patients who 
received only temozolomide. Of the 28 patients,  
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Table 1: Baseline patient characteristics 
 
















Mean age (years) 60±4.8 59±5.9 60±4.2 64±3.3 
Height (cm) 162±3.7 154±3.4 cm 156±5.2 149±4.4 
Weight (kg) 54±5.4 56±2.8 kg 60±3.6 63±4.7 
Type of treatment Temozolomide Radiotherapy Stem cell therapy Temozolomide, 
radiotherapy, 
stem cell therapy 








8 months 4 months 6 months 1 year 
 
          Table 2: Progression rates (%)  
 
Group 1 month 6 months 12 months Survival rate  
I  19 37 58 28 
II  21 34 49 28 
III  30 54 71 40 
IV 38 62 80 60 
 
Table 3: Side effects (N, %) in all groups 
 
Side effect Group I Group II Group III Group IV 
Nausea 3 (10.7%) 2 (7.1%) 2 (7.1%) - 
Vomiting 3 (10.7%) 2 (7.1%) 2 (7.1%) - 
Fever - - - 2 (7.1%) 
Neutropenia 2 (7.1%) - - 2 (7.1%) 
Fatigue - 1 (3.6%) - - 
Intracranial hemorrhage 1 (3.6%) - - - 
Seizures - 1 (3.6%) - - 
Thromboembolic disease - 2 (7.1%) - - 
Hematological toxicities  - 2 (7.1%) - - 
 
22 (78.6 %) completed radiation therapy on 
schedule. The ultimate survival rate of 28 % was 
similar to that of patients who received 
temozolomide only. 
 
The temozolomide and radiotherapy treatments 
did not differ significantly, and no gender-specific 
effect was evident. However, the between-group 
survival time differed (p < 0.06). Six (21.4 %) 
patients developed side effects: one (3.6 %) 
seizures, two (7.1 %) thromboembolic disease, 
one (3.6 %) fatigue, and two (7.1 %) 
hematological toxicities with nausea and vomiting 
(Table 3). 
 
Group III patients were of mean age 60 ± 4.2 
years, mean weight 60 ± 3.6 kg, and mean 
height 156 ± 5.2 cm (Table 1). They received 
bone marrow stem cells. The maximum 
improvement was 71 % and 40 % survived; this 
rate was better than those of Groups I and II 
(Table 2). Only two (7.1 %) patients developed 
side effects (nausea and vomiting).  No patient 
died during the course of the study (Table 3). 
 
Group IV patients were of mean age 64 ± 3.3 
years, mean weight 63 ± 3.7 kg, and mean 
height 149 ± 4.4 cm (Table 1). These patients 
received all three treatments. The temozolomide 
doses were 100 mg/m2 on each of 4 days (eight 
cycles) and the radiotherapy was identical to that 
received by Group II patients. The stem cell 
doses were identical to those of Group III. The 
maximum improvement was 80 %, thus better 
than that of the other three groups (Table 2). 
 
Two (7.1 %) patients developed neutropenia and 
fever. The survival rate was 60 %, which was 
better than those of the other three groups (Table 
3). CT scans showed significant improvement in 
most patients (Figure 2). 
 
A questionnaire was used to evaluate quality of 
life after completion of treatment. Group III and 
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IV patients reported better quality of life than 




Figure 2: CT scan taken after treatment with 




Tumor numbers in the elderly have increased 
dramatically in recent times. Many studies have 
described primary brain tumors in those aged ≥ 
60 years of age [16]. Clinicians face major 
challenges when treating gliomas in the elderly. 
Older age adversely affects the survival rate [17] 
and many other factors are also in play. Less 
toxic alternatives to radiotherapy and 
temozolomide are required [18]. 
 
We found that patients given mesenchymal stem 
cells, alone or in combination with other 
treatments, had fewer side effects, a better 
prognosis, and improved more than Group I and 
II patients (who received temozolomide and 
radiotherapy, respectively). Some patients could 
not tolerate the scheduled radiotherapy; this 
reduced the survival rate and worsened the 
prognosis [19]. 
 
We gave 30.0 Gy of radiotherapy, which was 
lower than that of the NOA-08 trial; in this latter 
trial, 60.0 Gy was delivered in fractions of 1.8 – 
2.0 Gy. In this previous study, the survival time 
was 9.6 months, whereas it was 1 year in the 
present study. This difference may be 
attributable to geographical variation, patients’ 
living conditions, and/or patient age [19]. 
 
The adverse effects that we encountered were 
similar to those of other studies. The maximum 
improvement afforded by temozolomide was 58 
%, similar to that of other studies in which 
temozolomide significantly improved survival and 
the quality of life. 
 
Gliomas are highly infiltrative and develop 
resistance to conventional therapies [20]. 
Mesenchymal stem cells from bone marrow 
afforded a maximum of 71 % improvement, 
which was better than that of conventional 
therapies. When stem cell therapy was combined 
with other therapies, survival and the quality of 
life improved to 80 %, showing that the stem 
cells were effective [21]. 
 
The results are in line with those of previous 
reports, highlighting the need for new alternative 





More research is required to obtain a deeper 
understanding of the utility of alternative 
therapies such as stem cells to improve the 
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